Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials
Open Access
- 1 February 2000
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 11 (2) , 151-156
- https://doi.org/10.1023/a:1008368319526
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), a novel topoisomerase I and II inhibitor, in cancer patientsAnti-Cancer Drugs, 1996
- Serum YKL-40: A new potential marker of prognosis and location of métastases of patients with recurrent breast cancerEuropean Journal Of Cancer, 1995
- Phase I study of RP 49532A, a new protein-synthesis inhibitor, in patients with advanced refractory solid tumorsCancer Chemotherapy and Pharmacology, 1995
- Phase I and pharmacokinetic study of a novel mitomycin C analog KW-2149Anti-Cancer Drugs, 1995
- How long have I got doctor?European Journal Of Cancer, 1994
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acidEuropean Journal Of Cancer, 1992
- Race, Nutritional Status, and Survival From Breast CancerJNCI Journal of the National Cancer Institute, 1990
- On the Nature and Ethics of Phase I Clinical Trials of Cancer ChemotherapiesJAMA, 1982
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958